It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

JBT Marel reports strong Q2 growth driven by the Marel acquisition and organic gains. Management reaffirms 2025 goals with ...

Aditya Infotech share price ended listing day at ₹1,085 on NSE, a 60.74% premium to the IPO price of ₹675, and at ₹1,084.10 ...

Explore the issues facing UnitedHealth Group Incorporated & Centene Corporation due to rising medical costs and regulatory ...

U.S. and foreign stocks, as well as bond ETFs, saw big inflows in July, putting the industry on pace for a record year with ...

All told, the S&P 500 rose 91.93 points to 6,329.94. The Dow Jones Industrial Average climbed 585.06 to 44,173.64, and the ...

The S&P 500 ended lower on Tuesday as unexpected weakness in U.S. services sector data raised fresh concerns about the ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

President Trump’s announcement of new tariffs on semiconductors and pharmaceuticals kept markets in flux. Plus: Drugmaker Pfizer boosted its annual profit guidance. And, data-software company Palantir ...

Key Points GAAP revenue surpassed expectations at $152.96 million in Q2 2025, beating estimates by 16.3%, but profitability missed, with GAAP EPS coming in at ($0.29) versus an expected GAAP EPS of ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...